Cytokinetics, Incorporated (NASDAQ: CYTK) is a Healthcare company (Biotechnology) with a market capitalization of $7.8B. The Maz Rating grades it against the other companies in its sector.
Cytokinetics, Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $56.13, Cytokinetics, Incorporated trades at 69.0x sales. Over the last twelve months it generated about $113M of revenue and a net loss of $840M. It runs a gross margin of 91.0%, an operating margin of -625.2% and a net margin of -686.6%. It shows return on equity of 157.1%, return on invested capital of -42.5% and a free cash flow yield of -7.5%. On the balance sheet: a debt-to-equity ratio of -3.96 and a current ratio of 3.36. Over the past 52 weeks the share price ranged from $53.55 to $88.31, with a beta of 0.36.
Cytokinetics, Incorporated does not currently pay a dividend.
35 Wall Street analyst ratings cover the stock: 34 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.